"So Bear the New data referenced in the PR is non existent?That is to say New data analysis."

The presentation slides are up as Jonzobot posted. New ALP data showing an apabetalone-mediated decrease consistent with the Phase 2 post-hoc analyses. Nothing new on eGFR. Some additional CKD subgroup demographic and on-treatment clinical chemistry measures are shown, which are new I think. 

BDAZ